David Baker

David Baker M.D. received his B.A. degree from McGill University in 1976, and his M.D. from the University of Pennsylvania in 1981. He has been a Board Certified Orthopaedic Surgion since 1992. Dr Baker was in private practice in orthopaedics from 1989 to 2011. He currently works at the Penn State Hershey Medical Center in the Department of Orthopaedics.

Tatiana Bizikova

Tatiana Bizikova M.Sc., RNDr. has worked at Royer since 1999. She has worked on exploration and development of time-release formulations, characterization of performance and determination of stability of pharmaceutical formulations. She has optimized processes for incorporation of pharmaceutical compounds into Royer biodegradable polymer matrices, and has developed and characterized new formulations. Currently, she manages regulatory administration and ongoing compliance. Prior to that, she served as a researcher at the Institute of Virology, Slovak Academy of Sciences, where she worked on the human tumor-associated protein MN/CA IX as a perspective biomarker for tumor diagnostics and potential therapeutic target. She also served as a researcher at the Cancer Research Institute, Slovak Academy of Sciences in Bratislava, Slovakia, focusing on the regulation of the growth factor expression in tumor cells and worked on evaluation of α2-macroglobulin as a modulator of melanoma cell growth. She holds a Master of Science degree and a Doctorate degree in Biochemistry from Comenius University, Bratislava, Slovakia.

John J. Byrne

John J. Byrne is a West Point graduate, and received his engineering degree in 1946. After serving in Korea, Japan and Saipan and at several army posts in the United States, he resigned as a Captain in 1954 and entered Georgetown Law School from which he received his JD in 1957. Byrne was a patent examiner at the United States Patent Office while in law school. For most of his legal career, Byrne was a partner in the international law firm of Baker & McKenzie where he started the patent and trademark section in their Washington D.C. office. After his retirement from Baker and McKenzie, he became President of Vycor, a software company. During his presidency, Vycor was successfully sold to the McAfee Corporation. Currently, in addition to his Royer duties, he is President and CEO of Byrne Capital, LLC and is manager of Wicklow Properties, LLC, both of which are investment vehicles in real estate and start-up companies that have a serious technology component.

Thomas Byrne

Thomas Byrne has directed Royers’s intellectual property strategy since the Company was founded. He is an experienced pharmaceutical development executive with special expertise in intellectual property law. His experience includes in-house counsel positions at both Genentech where he wrote the first patent application relating to Herceptin®, and Amgen where he prosecuted applications relating to Epogen® and Neupogen®. While at Amgen, he also co-invented the technology behind the blockbuster drug darbepoietin alpha (Aranesp®). From 1992-2000 he was a partner in the intellectual property law firm of Nixon and Vanderhye P.C. (Arlington, VA). Mr. Byrne is currently a board member and consultant for several start-up biotechnology and pharmaceutical companies. He holds BS degrees from the University of Virginia in Chemical Engineering and Nuclear Engineering, an MS degree from Yale University in Biochemical Engineering, and a law degree from the University of Virginia.

Stephen C. Nudel

Stephen C. Nudel has been practicing law since 1984, and he founded the Law Offices of Stephen C. Nudel, PC in 1998. A graduate of the Duquesne University School of Law and George Washington University, Mr. Nudel has been counsel to businesses that range from business start-ups to Fortune 100 companies. He has effectively represented and orchestrated investor financial investments and exits, commercial real estate developments, and corporate mergers. He has represented angel investors and companies in capital generation. In addition to his duties as an active Royer board member, he continues to practice law specializing in corporate, real estate and technology legal matters.

Martha Spano

Martha Spano holds a Masters of Science degree in Biochemistry. She is a scientist who has worked for multiple companies in the biotech, drug discovery, and separation chemistry industries, as well as in academia. She has direct experience in drug delivery technologies and how drugs are moved through regulatory pipelines. Currently, Ms. Spano is a researcher in the Cell Biology Department at the University of Virginia.